Real-World Study of Delgocitinib Cream for Chronic Hand Eczema
Part of Skin clinical trials.
This study tracks how well delgocitinib cream works and how safe it is for people with chronic hand eczema in everyday use. Researchers collect information from your doctor visits to understand if this treatment helps manage your hand eczema symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with chronic hand eczema (long-lasting eczema affecting your hands)
- Your doctor believes delgocitinib cream is appropriate for you to try
- You have not previously used delgocitinib cream
- You are not currently enrolled in another clinical trial, or have not been in one in the past 12 months
- You are willing to provide written consent and let researchers review your medical records
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information about how well medications work for chronic hand eczema and how safe they are over time. You'll share your health data and treatment experiences through simple online forms to help doctors better understand which treatments work best.
This trial studies chronic hand eczema (and sometimes related atopic skin disease) to better understand your condition and what may be going on in the skin. You may be asked to follow a study plan for a set period and avoid certain treatments just before joining.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This study looks at how certain proteins and channels in the body affect pain and itching. Healthy people will have a small test area on their forearm treated with a study drug to see if it changes how they feel pain or itch.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This trial tests a cream called delgocitinib for adults with lichen sclerosus in the genital area. It aims to see if the cream can safely and effectively reduce symptoms over 52 weeks.
Hear when a new Chronic Hand Eczema (CHE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.